Exelixis, Inc. Announces July 26 Conference Call Update on Developments Under the Collaboration With GlaxoSmithKline

SOUTH SAN FRANCISCO, Calif., July 25 /PRNewswire-FirstCall/ -- Exelixis, Inc. will hold a live conference call on Thursday, July 26, at 5:00 a.m. PDT/8:00 a.m. EDT, in which Exelixis management will provide an update on developments under its collaboration with GlaxoSmithKline. Domestic callers may participate in the conference call by dialing 866-825-3308, and international callers may participate by dialing 617-213-8062. Participant passcode number is 51734674.

An archive of this call will be available until 9:00 p.m. PDT/12:00 a.m. EDT on August 30, 2007. Access numbers for this replay are 888-286-8010 (domestic) and 617-801-6888 (international). The replay passcode is 16500067. The discussion will also be webcast and may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

Exelixis, Inc.

CONTACT: investors, Charles Butler, Director, Investor Relations,+1-650-837-7277, cbutler@exelixis.com, or media, Hal Mackins, CorporateCommunications, +1-650-837-7012, hmackins@exelixis.com, both of Exelixis,Inc.

Back to news